RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:545

Follicular lymphoma

high confidenceDisorder

Publications

30,967

98.3th percentile

Trials

775

Interventional, condition-specific

Researchers

1,509

Distinct authors in sample

Gene link

—

Readiness

5/6

Stages with a signal

Clinical definition (Orphanet)

Follicular lymphoma is a form of non-Hodgkin lymphoma characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.

How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (9)

follicle center lymphoma · follicle centre lymphoma · follicular center cell lymphoma · follicular centre cell lymphoma · follicular non-Hodgkin lymphoma · follicular non-Hodgkin's lymphoma · lymphoma, follicular center cell · lymphoma, follicular centre cell · lymphoma, follicular, malignant

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

5/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    30,967 matched papers (17,982 in last 10 years) Source

  3. Phenotype characterisedPresent

    17 HPO annotations (e.g. Lymphoma; Meningitis; Abnormal peritoneum morphology) Source

  4. Animal modelPresent

    4 genotype models (Mus musculus) Source

  5. Orphan designationPresent

    11 FDA · 9 EMA designations (11 FDA orphan-indication approvals) — e.g. tafasitamab-cxix Source

  6. Interventional trialPresent

    775 matched on ClinicalTrials.gov (140 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

17

Associated phenotypes · MONDO:0018906

  • Lymphoma
  • Meningitis
  • Abnormal peritoneum morphology
  • Hypercalcemia
  • Increased circulating lactate dehydrogenase concentration

Showing 5 of 17 — open Monarch for the full list.

Animal models (Monarch / Alliance)

4

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

30

Designations · 11 with FDA orphan-indication approval

  • FDA tafasitamab-cxixfollicular lymphoma · 2021-01-07 · Not FDA Approved for Orphan Indication
  • FDA tisagenlecleucelfollicular lymphoma · 2020-09-16 · Not FDA Approved for Orphan Indication
  • FDA Parsaclisibfollicular lymphoma · 2019-09-25 · Not FDA Approved for Orphan Indication
  • FDA apilimod dimesylatefollicular lymphoma · 2019-07-01 · Not FDA Approved for Orphan Indication
  • FDA mosunetuzumabfollicular lymphoma · 2018-12-17 · Not FDA Approved for Orphan Indication
  • FDA pembrolizumabfollicular lymphoma · 2017-06-06 · Not FDA Approved for Orphan Indication
  • FDA daratumumabfollicular lymphoma · 2015-08-06 · Not FDA Approved for Orphan Indication
  • FDA ibrutinibfollicular lymphoma · 2014-09-08 · Not FDA Approved for Orphan Indication

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

211

Drugs / clinical candidates · MONDO_0018906

CTD chemicals (MyDisease.info)

18 associated chemicals · 260 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol · therapeutic
  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine · therapeutic
  • alfacalcidol · therapeutic
  • BACOD protocol · therapeutic
  • CHOP protocol · therapeutic
  • COP protocol 2 · therapeutic
  • COPP protocol · therapeutic
  • ESAP protocol · therapeutic
  • Etoposide · therapeutic
  • Ifosfamide · therapeutic
  • MCP protocol · therapeutic
  • Mitoxantrone · therapeutic

Pathways: Oxidative phosphorylation; Pyrimidine metabolism; Cysteine and methionine metabolism; Lysine degradation; Selenocompound metabolism; Sphingolipid metabolism; One carbon pool by folate; Metabolic pathways

MyDisease.info · MONDO:0018906

Literature

Is anyone studying this?

30,967

30,967 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

30,967 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

17,982 in the last 10 years · high confidence · 98.3th percentile (publications denominator)

Phrase hits: 30,967 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,509

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y10 papers · 2026

    Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

    Papers in Europe PMC
  2. 02
    Izutsu K5 papers · 2026

    National Cancer Center Hospital, Tokyo, Japan.

    Papers in Europe PMC
  3. 03
    Jiménez-Ubieto A4 papers · 2026

    Hospital Universitario 12 de Octubre, Complutense University, CNIO, Centro de Investigación Biomédica en Red-Cáncer (CIBERONC), Madrid, Spain.

    Papers in Europe PMC
  4. 04
    Luminari S4 papers · 2026

    Azienda Unità Sanitaria Locale, IRCCS Reggio Emilia, Reggio Emilia, Italy.

    Papers in Europe PMC
  5. 05
    Quintanilla-Martinez L4 papers · 2026

    Institute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard-Karls-University of Tübingenand, University Hospital Tübingen, Tübingen, Germany. Leticia.Quintanilla-Fend@med.uni-tuebingen.de.

    Papers in Europe PMC
  6. 06
    Bar M3 papers · 2026

    Bristol Myers Squibb, Boudry, Switzerland.

    Papers in Europe PMC
  7. 07
    Bosch-Schips J3 papers · 2026

    Institute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard-Karls-University of Tübingenand, University Hospital Tübingen, Tübingen, Germany.

    Papers in Europe PMC
  8. 08
    Cartron G3 papers · 2026

    CHU Montpellier UMR5535, Montpellier, France.

    Papers in Europe PMC
  9. 09
    Cerhan JR3 papers · 2026

    Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.

    Papers in Europe PMC
  10. 10
    Chen Z3 papers · 2026

    School of Clinical Dentistry, Faculty of Health, University of Sheffield, Sheffield, UK.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

775

interventional trials for this specific condition

775 interventional trials matched this specific condition name; 140 currently recruiting in our sample.

Data as of 11 September 2026

775 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.8th percentile).

high confidence · 99.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

775 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

82 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 96 · after dedupe 93 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 93 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (93)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Follicular lymphoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Follicular lymphoma" OR "follicle center lymphoma" OR "follicle centre lymphoma" OR "follicular center cell lymphoma" OR "follicular centre cell lymphoma" OR "follicular non-Hodgkin lymphoma" OR "follicular non-Hodgkin's lymphoma" OR "lymphoma, follicular center cell" OR "lymphoma, follicular centre cell" OR "lymphoma, follicular, malignant"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Follicular lymphoma" OR "follicle center lymphoma" OR "follicle centre lymphoma" OR "follicular center cell lymphoma" OR "follicular centre cell lymphoma" OR "follicular non-Hodgkin lymphoma" OR "follicular non-Hodgkin's lymphoma" OR "lymphoma, follicular center cell" OR "lymphoma, follicular centre cell" OR "lymphoma, follicular, malignant"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 775 interventional · 82 observational · 4 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T14:16:52.286Z